Standout Papers

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6):... 2012 2026 2016 2021 451
  1. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study (2012)
    John B. Buse, Michael A. Nauck et al. The Lancet

Immediate Impact

1 by Nobel laureates 4 from Science/Nature 94 standout
Sub-graph 1 of 21

Citing Papers

GLP-1-based therapies for diabetes, obesity and beyond
2025 Standout
Adipose tissue retains an epigenetic memory of obesity after weight loss
2024 StandoutNature
7 intermediate papers

Works of Cory R. Heilmann being referenced

Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes
2017
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
2012 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Cory R. Heilmann 1024 45 564 392 19 1.4k
Lisa E. Porter 1118 30 558 347 10 1.4k
Kenneth Mace 1028 44 457 634 34 1.6k
Marcin Zychma 1420 19 780 550 24 1.7k
Karen Tornøe 1061 59 541 470 28 1.5k
Anne Bloch Thomsen 1255 21 677 464 25 1.5k
Daniel R. Quast 967 106 469 437 30 1.4k
Mads Axelsen 926 75 510 380 14 1.6k
Ambady Ramachandran 1421 59 560 437 9 1.5k
Florian M.M. Baeres 822 106 438 405 30 1.6k
Phil Ambery 856 41 438 387 54 1.3k

All Works

Loading papers...

Rankless by CCL
2026